Clinical Study of YYJD Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma

Inclusion Criteria:

* Pathologically or cytologically confirmed stage IIIa-IV pulmonary adenocarcinoma;
* With activating EGFR mutation (either exon19del or exon21L858R) and one month of gefitinib as first-line or second-line therapy without disease progression (PD);
* With TCM diagnostic pattern Qin-and-yin dificiency;
* Age ≥18 years old;
* Estimated life expectancy of at least 12 weeks;
* Without major organ dysfunction: hemoglobin ≥9 g/dL, absolute neutrophil count (ANC) ≥1.5\*109/L, platelets ≥100 \*109/L,bilirubin ≤1.5ULN, alkaline phosphatase (AP), aspartate transaminase (AST) and alanine transaminase (ALT) ≤2.5 upper limited number(ULN) (AP, AST, ALT ≤5ULN is acceptable with liver metastasis).INR≤1.5, APTT in the normal range( 1.2DLN-1.2ULN),creatinine ≤1.5ULN;

Exclusion Criteria:

* with other malignant tumor except NSCLC 5 years previous to study entry;
* PD after onee month of gefitinib treatment
* Estimated life expectancy less than 12 weeks;
* Brain metastasis with relevant symptoms
* History of cardiovascular disease: Congestive Heart Failure \> grade II in NYHA.Unstable angina patients (have angina symptoms in rest) or a new occurrence of angina (began in the last 3 months) or myocardial infarction happens in the last 6 months;
* Pregnant or child breast feeding women;

  * Mental or cognitive disorders;